Can neuronal surface antibodies alter synaptic function without proving active autoimmune brain disease?

Neuronal surface antibodies can be biologically active, but a positive broad serum IgG/IgA panel is not itself evidence of active autoimmune encephalitis or another autoimmune brain disorder.

Mechanistic evidence

• Patient-derived anti-NMDAR IgG can crosslink and internalize surface GluN1-containing NMDARs, reducing NMDAR-mediated synaptic currents and hippocampal long-term potentiation. Passive-transfer models reproduce reduced hippocampal receptor expression, impaired plasticity, and reversible behavioral effects.
• Effects differ by target: AMPAR antibodies promote receptor internalization; GABA-B receptor antibodies can functionally antagonize signaling (including reduced baclofen responses); LGI1 and CASPR2 antibodies disrupt protein complexes important for AMPAR organization and Kv1-channel clustering, respectively, potentially producing network hyperexcitability.
• Thus, a genuinely pathogenic antibody can impair synaptic function without complement-mediated neuronal destruction.

Diagnostic interpretation

• Serum reactivity must be interpreted against a compatible neurologic syndrome and objective findings from MRI, EEG, and CSF. In one cohort, unrestricted neuronal-antibody panel testing had a positive predictive value of only 17%; restricting testing with a clinical risk score increased this to 42%.
• Low-titer, phenotype-discordant, isolated cell-based-assay, or line-blot serum results are particularly vulnerable to false-positive or clinically irrelevant interpretation.
• Paired serum–CSF testing is important: CSF is especially informative for NMDAR and GFAP antibodies, whereas serum may be more sensitive for LGI1 and some paraneoplastic antibodies. Discordant serum-positive/CSF-negative findings should be confirmed with an orthogonal method, such as tissue-based immunohistochemistry/immunofluorescence, live-neuron assay, or reference-laboratory repeat testing.

Bottom line

• A broad serum IgG/IgA-positive result is a lead for focused evaluation—not proof of active autoimmune brain disease. Diagnosis should rest on the clinical phenotype, MRI/EEG/CSF correlation, and target-appropriate confirmatory testing.